The Chronic Gout Market is Expected to Witness Remarkable Growth at a CAGR of 5.44% During the Study Period (2018-30), Assesses DelveInsight

The Chronic Gout market size is growing during the forecast period owing to the launch of upcoming therapies by the key pharma companies such as Jiangsu Atom Bioscience and Pharmaceutical, Arthrosi Therapeutics, Teijin Pharma, Selecta Biosciences, Inc., Shanton Pharma, among others and increasing prevalence of Gout.

LAS VEGAS, May 25, 2022 /PRNewswire/ -- DelveInsight's Chronic Gout Market Insights report includes a comprehensive understanding of current treatment practices, Chronic Gout emerging drugs, market share of individual therapies, and current and forecasted market size from 2018 to 2030, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Takeaways from the Chronic Gout Market

• According to DelveInsight estimates, the Chronic Gout market size was approximately USD 2,613.1 million in 2020.
• As per analysis, the total Chronic Gout prevalent cases were found to be more than 2 million in the 7MM in 2018. 
• Key Chronic Gout companies such as Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., Jiangsu Atom Bioscience and Pharmaceutical, Arthrosi Therapeutics, Teijin Limited, Selecta Biosciences, Inc., Shanton Pharma, and others are currently working to develop novel Chronic Gout drugs which can be available in the Chronic Gout market in the upcoming years.
• The Chronic Gout therapies in the pipeline include ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and others.
• The key driver for the surge in Chronic Gout market size is the rise in the number of prevalent cases of Chronic Gout in 7MM.

Discover more about therapies set to grab major Chronic Gout market share @ Chronic Gout Market Landscape

Chronic Gout

Gout is a chronic disease characterized by the deposition of monosodium urate (MSU) crystals. Gout often manifests as an acute, self-limiting inflammatory monoarthritis of the lower limb joints. Chronic Gout is defined by long-term joint inflammation that causes joint discomfort at rest and during activity. Among the most common Chronic Gout causes is hyperuricemia. Higher serum urate levels are associated with an increased risk of gout flare-ups and more frequent flare-ups over time.

The most common Chronic Gout symptom is intense joint pain, followed by discomfort, inflammation, and redness. In the setting of acute inflammatory arthritis, laboratory confirmation of synovial fluid MSU is required for a definitive Chronic Gout diagnosis. As a result, a systematic review comparing the accuracy of tests used to diagnose Chronic Gout, such as physical findings, serum UA, ultrasound (US), plain radiography, and dual-energy computed tomography (DECT), to synovial fluid UA can be used to inform clinical decision-making for patients and providers, as well as improve the quality of care for gout patients in the primary and acute care setting.

Chronic Gout Epidemiology Segmentation

As per DelveInsight, there were more than 2 million Chronic Gout prevalent cases in the 7MM in 2018

Among EU5 countries, Germany had the highest Chronic Gout prevalence in 2018.

The Chronic Gout Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Total Prevalent cases of Gout
• Total Prevalent cases of Chronic Gout 
• Gender-specific Prevalent Cases of Chronic Gout
• Total Prevalent Cases of Chronic Gout based on Risk Factors

Download the report to understand which factors are driving Chronic Gout epidemiology trends @ Chronic Gout Epidemiological Insights

Chronic Gout Treatment Market

Gout treatment focuses on two areas: reducing gout inflammation and pain associated with gout and preventing gout complications by lowering blood urate levels. Gout management encompasses flare management, chronic gout management, flare avoidance, and comorbidity control. Newer Chronic Gout drugs in the pharmacological arsenal are proving effective and are supplementing previous ones. Other significant aspects of its care include patient education, dietary and lifestyle modifications, and the discontinuation of hyperuricemic drugs.

The major Chronic Gout therapies available in the Chronic Gout market are aimed at timely relief of pain and disability caused by intense inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as colchicine, are commonly used as the first line of therapy for Chronic Gout treatment. However, glucocorticoids or corticotropin are used when NSAIDs and colchicine are contraindicated. 

Moreover, apart from these several drugs are also used for Chronic Gout treatment. Drugs such as Febuxostat, KRYSTEXXA (pegloticase injection), Topiroxostat (FYX-051), and Xanthine oxidase inhibitors (XOIs) are approved by the FDA for the Chronic Gout treatment.

To know more about how to treat Chronic Gout visit @ Chronic Gout Treatment Guidelines

Chronic Gout Pipeline Therapies and Key Companies

• ABP 671: Jiangsu Atom Bioscience and Pharmaceutical
• AR-882 Arthrosi Therapuetics
• TMX-049 Teijin Limited
• Pegadricase-SVP: Selecta Biosciences, Inc.
• SAP 001: Shanton Pharma

Learn more about the chronic gout drugs in the pipeline @ Chronic Gout Medication

Chronic Gout Market Dynamics

The Chronic Gout market is shifting positively as the gout incidence and prevalence have risen dramatically in recent decades. Gout treatment in individuals with concomitant metabolic syndrome and comorbid conditions such as renal impairment was challenging until recently due to restricted therapeutic choices in the Chronic Gout market. However, great improvement has been achieved in recent years, with the advent of novel drugs for Chronic Gout, such as febuxostat and pegloticase. Many other drugs with a rational mechanism of action are in development and will most likely be launch in the coming years in the Chronic Gout market. Thus, a new era in the area of gout has begun which will further drive the Chronic Gout market forward. At present, Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., and others are actively working in the Chronic Gout market towards the development of potential therapy to overcome the unmet medical needs of the currently used therapeutics.

Other factors that will accelerate the growth of the Chronic Gout market during the forecasted period (2021–2030) are treat-to-target strategy and management and improvements in imaging techniques. In addition, a better understanding of the disease pathophysiology will also aid in the development of new treatment options in the Chronic Gout market.

However, certain factors are hindering the growth of the Chronic Gout market. There is a pervasive dearth of information and understanding about gout care among both patients and doctors. Although gout is treatable, a lack of understanding leads to underdiagnosis and undertreatment, particularly in individuals who do not meet the 'stereotypical gout' profile (for example, younger patients). In addition, factors such as inadequate monitoring and care and stigma related to Chronic Gout are also acting as a barrier to the Chronic Gout market growth.

Scope of the Chronic Gout Market Report

• Study Period: 2018-2030
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Gout Companies: Teijin Pharma, Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., Jiangsu Atom Bioscience and Pharmaceutical, Arthrosi Therapeutics, Teijin Limited, Selecta Biosciences, Inc., Shanton Pharma, and others
• Key Chronic Gout Therapies: ABP 671, AR-882, TMX-049, Pegadricase-SVP, SAP 001, and others
• Therapeutic Assessment: Chronic Gout current marketed and emerging therapies
• Chronic Gout Market Dynamics:  Chronic Gout market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Chronic Gout Market Access and Reimbursement

Discover more about the Chronic Gout management @ Drugs for Chronic Gout 

Table of Contents

Get in touch with our Business executive @ Healthcare Due Diligence Services 

Related Reports

Chronic Gout Epidemiology

Chronic Gout Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Chronic Gout epidemiology in the 7MM.

Chronic Gout Pipeline

Chronic Gout Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chronic Gout companies involved such as Arthrosi Therapeutics, Teijin Limited, Selecta Biosciences, Inc., among others.

Chronic Refractory Gout Epidemiology

Chronic Refractory Gout Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Chronic Refractory Gout epidemiology in the 7MM.

Chronic Refractory Gout Market

Chronic Refractory Gout Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Chronic Refractory Gout companies such as Horizon Therapeutics, Sanwa Kagaku Kenkyusho Co. Ltd., among others.

Gout Market

Gout Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Gout companies such as Jiangsu Hengrui Medicine, Selecta Biosciences, LG Chem, among others.

Gout Pipeline

Gout Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Gout companies involved such as Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, among others.

Other Trending Reports

Tuberculosis Market

The Tuberculosis Market research report delivers an in-depth understanding of the Tuberculosis, historical and forecasted epidemiology as well as the Tuberculosis Market size, share, and trends in the 7MM. Some of the key companies in the Tuberculosis Market include Serum Institute of India, AnHui Longcom Biologic Pharmacy, Biofabri, Immunitor, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma, LegoChem Biosciences, Quratis, Aeras, Qurient, Sequella, Otsuka Pharmaceutical, Vaxil Biotherapeutics, Faron Pharmaceuticals, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, Spero Therapeutics, and others.

Post-Polycythemia Vera Myelofibrosis Market

The Post-Polycythemia Vera Myelofibrosis Market research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Post-Polycythemia Vera Myelofibrosis market size, share, and trends in the 7MM. Some of the key companies in the Post-Polycythemia Vera Myelofibrosis Market include Sierra Oncology, CTI Biopharma, Incyte Corporation, Imago BioSciences, Hoffmann-La Roche, Kartos Therapeutics, and others.

Diverticulitis Market

The Diverticulitis Market research report delivers an in-depth understanding of the diseases, historical and forecasted epidemiology as well as the Diverticulitis market size, share, and trends in the 7MM. Some of the key companies in the Diverticulitis Market include Cosmo Pharmaceuticals, Salix Pharmaceuticals, Emmaus Medical, and others.

Lipodystrophy Market

The Lipodystrophy Market research report delivers an in-depth understanding of the Lipodystrophy, historical and forecasted epidemiology as well as the Lipodystrophy market size, share, and trends in the 7MM. Some of the key companies in the Lipodystrophy Market include Cell Praxis, Carmot Therapeutics, Ionis Pharmaceuticals, Galmed Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Cadila, and Others. 

Primary Open Angle Glaucoma (POAG) Market

The Primary Open Angle Glaucoma (POAG) Market research report delivers an in-depth understanding of the POAG, historical and forecasted epidemiology as well as the POAG market size, share, and trends in the 7MM. Some of the key companies in the POAG market include Laboratorios Sophia, Aerie Pharmaceuticals, Santen Pharmaceuticals, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Aerpio Therapeutics, Whitecap Biosciences, Occular Therapeutics, and Others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg